^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MK-3120

    i
    Other names: MK-3120, SKB410, SKB-410, SKB 410, MK 3120, MK3120
    Associations

    News

    Trials
    Company:
    Merck (MSD), Sichuan Kelun Pharma
    Drug class:
    Topoisomerase I inhibitor, Nectin-4-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    10d
    A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) (clinicaltrials.gov)
    P1/2, N=270, Recruiting, Merck Sharp & Dohme LLC | N=68 --> 270
    Enrollment change
    |
    MK-3120
    10d
    KEYMAKER-U04 substudy 04A: A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) (clinicaltrials.gov)
    P1/2, N=48, Recruiting, Merck Sharp & Dohme LLC | Active, not recruiting --> Recruiting | Trial completion date: Jun 2028 --> Jun 2030 | Trial primary completion date: Jun 2028 --> Jun 2030
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • zilovertamab vedotin (MK-2140) • MK-3120
    15d
    KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=55, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2030 --> Jul 2031 | Trial primary completion date: Oct 2030 --> Jul 2031
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • MK-3120
    1m
    KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=55, Recruiting, Merck Sharp & Dohme LLC
    Trial initiation date
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • MK-3120
    1m
    A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Merck Sharp & Dohme LLC
    Trial initiation date
    |
    MK-3120
    3ms
    A clinical study of MK-3120 in people with bladder cancer (MK-3120-003) (2025-520467-40-00)
    P1/2, N=32, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    MK-3120
    3ms
    A clinical study of new treatments given with enfortumab vedotin and pembrolizumab in people with urothelial cancer (MK-3475-04D) (2025-522253-19-00)
    P1/2, N=16, Recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • MK-3120
    4ms
    KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=55, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • MK-3120
    6ms
    A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) (clinicaltrials.gov)
    P1/2, N=270, Recruiting, Merck Sharp & Dohme LLC | N=180 --> 270 | Trial completion date: Jan 2028 --> Mar 2031 | Trial primary completion date: Jan 2028 --> Oct 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    MK-3120
    6ms
    KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=55, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • MK-3120
    6ms
    A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MK-3120
    6ms
    A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) (clinicaltrials.gov)
    P1/2, N=45, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    MK-3120